{"id":60005,"date":"2024-09-13T13:05:02","date_gmt":"2024-09-13T11:05:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/"},"modified":"2024-09-13T13:05:02","modified_gmt":"2024-09-13T11:05:02","slug":"repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/","title":{"rendered":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024"},"content":{"rendered":"
\n

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1\/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain.\n<\/p>\n

\nTRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1\/2 dose-escalation and expansion study designed to establish the recommended Phase 2 dose (RP2D) and schedule. The study evaluated safety, pharmacokinetics and identify preliminary anti-tumor activity associated with camonsertib monotherapy in patients with solid tumors (Module 1).\n<\/p>\n

\nOral Presentation Details:<\/b>\n<\/p>\n

\nTitle:<\/b> Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
\n
Presenter:<\/b> Benedito A. Carneiro, MD, Legorreta Cancer Center, Division of Hematology\/Oncology, The Warren Alpert Medical School, Brown University, Providence, RI
\n
Presentation number:<\/b> 619MO
\n
Session:<\/b> Mini Oral Session: Developmental Therapeutics
\n
Session date and time:<\/b> Saturday, September 14 | 8:45 a.m. \u2013 10:15 a.m. ET
\n
Session location:<\/b> Oviedo Auditorium, Hall 3\n<\/p>\n

\nAbout Repare Therapeutics, Inc.<\/b>\n<\/p>\n

\nRepare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx\u00ae platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company\u2019s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1\/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1\/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Pol\u03b8 ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com<\/a> and follow @Reparerx on X (formerly Twitter) and LinkedIn.\n<\/p>\n

\nSNIPRx\u00ae is a registered trademark of Repare Therapeutics Inc.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations & Media:<\/b>
Robin Garner
\n
Vice President and Head of Investor Relations
\n
Repare Therapeutics Inc.
\n
investor@reparerx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1\/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60005","6":"format-standard","7":"category-industry"},"yoast_head":"\nRepare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1\/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-13T11:05:02+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Repare Therapeutics to Present Data from Phase 1\\\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024\",\"datePublished\":\"2024-09-13T11:05:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/\"},\"wordCount\":337,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/\",\"name\":\"Repare Therapeutics to Present Data from Phase 1\\\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-09-13T11:05:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repare Therapeutics to Present Data from Phase 1\\\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/","og_locale":"en_US","og_type":"article","og_title":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend","og_description":"CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1\/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-09-13T11:05:02+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024","datePublished":"2024-09-13T11:05:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/"},"wordCount":337,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/","url":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/","name":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-09-13T11:05:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-camonsertib-monotherapy-in-multiple-advanced-solid-tumors-harboring-atm-loss-of-function-at-esmo-congress-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Repare Therapeutics to Present Data from Phase 1\/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60005"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60005\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}